{"meta":{"query_hash":"817cea60e012","filters":{"venue":"Expert Opinion on Emerging Drugs"},"cohort_total":45,"direct_labels_cover":0,"predictions_cover":45,"exported":45,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/817cea60e012","api":"https://metacan.xera.ac/api/v1/cohort?venue=Expert+Opinion+on+Emerging+Drugs"},"results":[{"id":"W1974479297","doi":"10.1517/14728214.2014.955014","title":"Emerging drugs for levodopa-induced dyskinesia","year":2014,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University Health Network","funders":"","keywords":"Levodopa; Medicine; Dyskinesia; Intensive care medicine; Disease; Parkinson's disease; Internal medicine","score_opus":0.05619929424255898,"score_gpt":0.39023074936603563,"score_spread":0.33403145512347665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974479297","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006920997,0.9974986,0.00010847483,0.00044052044,0.0002875063,0.000011206691,0.000027516384,0.000010848449,0.0015461348],"genre_scores_gemma":[0.00070406304,0.99687696,0.0002494328,0.00053632725,0.00023547122,0.000013140996,0.000055725828,0.0000021837568,0.0013265761],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997857,0.00003745261,0.000031032876,0.00003622852,0.0000887865,0.000020831903],"domain_scores_gemma":[0.9997278,0.00009331292,0.00006280903,0.000007941263,0.00008639166,0.000021724421],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045912556,0.0009772959,0.0012356015,0.0021829512,0.00026383004,0.0008799512,0.00076987705,0.0012918463,0.009236891],"category_scores_gemma":[0.00054605,0.00018833556,0.0006917722,0.0020533185,0.0003949092,0.0011561722,0.00056532957,0.002253695,0.005236695],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007109732,0.00005848406,0.00008556946,0.021074312,0.000091942646,0.00022495561,0.000045282715,0.00014168085,0.0015303482,0.0030325323,0.051149324,0.92249453],"study_design_scores_gemma":[0.000031064537,0.00007063163,0.0004933604,0.006301038,0.00013360927,0.0013084074,0.00003673593,0.00006519624,0.0003518068,0.0013795162,0.9898179,0.000010743646],"about_ca_topic_score_codex":0.0010799828,"about_ca_topic_score_gemma":0.0025170734,"teacher_disagreement_score":0.009236891,"about_ca_system_score_codex":0.00074050284,"about_ca_system_score_gemma":0.0010671137,"threshold_uncertainty_score":0.030900538},"labels":[],"label_agreement":null},{"id":"W1985544005","doi":"10.1517/14728214.2013.811487","title":"Inflammation and the heart – prime time for new therapeutic approaches","year":2013,"lang":"en","type":"letter","venue":"Expert Opinion on Emerging Drugs","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"","keywords":"Medicine; Coronary artery disease; Inflammation; Disease; Intensive care medicine; Clinical trial; Atherosclerotic cardiovascular disease; Cardiology; Internal medicine","score_opus":0.037059422539979,"score_gpt":0.2852610698547764,"score_spread":0.24820164731479738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985544005","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030461748,0.0997012,0.0005063586,0.8340776,0.062073573,0.000016925589,0.000054538865,0.00006621608,0.0031989347],"genre_scores_gemma":[0.0053270576,0.09977016,0.0008192983,0.5523673,0.33465025,0.000043671345,0.000074519776,0.00003461627,0.0069130445],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981875,0.0004878726,0.00018506293,0.00028440592,0.00065952464,0.00019555807],"domain_scores_gemma":[0.9964224,0.0019897404,0.00024987062,0.00013909994,0.0007734937,0.00042534227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019623665,0.0009874357,0.0018145785,0.000741413,0.0012943693,0.0024572648,0.0009912807,0.015961519,0.007822689],"category_scores_gemma":[0.0071292683,0.00036559993,0.0009978233,0.00047177097,0.0026582566,0.0047211624,0.0014312242,0.02862919,0.0077478965],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010523281,0.00004797021,0.00016965205,0.00060325756,0.000027442615,0.0027097655,0.00009793915,0.00009841346,0.0007304525,0.008230818,0.9109627,0.07621639],"study_design_scores_gemma":[0.00008590924,0.0001024249,0.00036733955,0.0011163612,0.00002238402,0.0048466055,0.00015581795,0.00015752258,0.0002008339,0.013995105,0.97891814,0.00003154318],"about_ca_topic_score_codex":0.00068002363,"about_ca_topic_score_gemma":0.0013148015,"teacher_disagreement_score":0.015961519,"about_ca_system_score_codex":0.0025197961,"about_ca_system_score_gemma":0.0018359517,"threshold_uncertainty_score":0.026169538},"labels":[],"label_agreement":null},{"id":"W1999827505","doi":"10.1517/14728214.11.2.275","title":"Emerging drugs for the treatment of chronic obstructive pulmonary disease","year":2006,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; COPD; Roflumilast; Pulmonary disease; Intensive care medicine; Pharmacology; Immunology; Internal medicine","score_opus":0.039661724835240206,"score_gpt":0.3782209013057312,"score_spread":0.338559176470491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999827505","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015954873,0.99445844,0.00027565024,0.001189713,0.0009346611,0.000023482098,0.000024277644,0.000016759923,0.0029175032],"genre_scores_gemma":[0.0007152495,0.9940116,0.00073060335,0.0009857616,0.0007548476,0.00002250582,0.000054705753,0.000002610149,0.0027221448],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995778,0.00007757061,0.00004159054,0.000047758927,0.00021710758,0.000038183756],"domain_scores_gemma":[0.9995913,0.00010978559,0.00006725339,0.000017846498,0.00015113827,0.00006277416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009863798,0.0010776488,0.0014756176,0.002126448,0.0004028426,0.00088280905,0.001018598,0.0020321792,0.010166956],"category_scores_gemma":[0.00074589887,0.0002537102,0.0007227355,0.001713041,0.00052320486,0.001627814,0.0007504348,0.0028497456,0.008499959],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001124641,0.00015973611,0.00012123225,0.0066266204,0.00008681663,0.0003101331,0.000057575187,0.0001853855,0.0027090074,0.003279849,0.06366787,0.92268336],"study_design_scores_gemma":[0.00007964553,0.00017055986,0.00043523987,0.0014317778,0.00006799066,0.0010095465,0.00003345257,0.00007212832,0.00034145397,0.0012514029,0.99509573,0.00001112315],"about_ca_topic_score_codex":0.0010227944,"about_ca_topic_score_gemma":0.002902948,"teacher_disagreement_score":0.010166956,"about_ca_system_score_codex":0.0006855848,"about_ca_system_score_gemma":0.0013058151,"threshold_uncertainty_score":0.03401184},"labels":[],"label_agreement":null},{"id":"W2001823700","doi":"10.1517/14728210903142147","title":"Emerging drugs for prostate cancer","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Angiogenesis; Androgen receptor; Pharmacology; Matrix metalloproteinase inhibitor; Tyrosine kinase; Cancer; Cancer research; Matrix metalloproteinase; Internal medicine; Receptor","score_opus":0.0657725239338676,"score_gpt":0.44593343913200534,"score_spread":0.38016091519813777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001823700","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014863812,0.991508,0.0003605696,0.0007210549,0.0009606903,0.000028859035,0.000051558338,0.000029496703,0.0061911293],"genre_scores_gemma":[0.0011259596,0.9880642,0.0009413815,0.0012756032,0.0006280077,0.000039898976,0.00014459214,0.0000065619165,0.007773704],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997216,0.00005197756,0.000024259127,0.000043697506,0.00013037257,0.000028007906],"domain_scores_gemma":[0.9997851,0.0000691868,0.00003819579,0.000012254803,0.00006451988,0.00003081351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048051775,0.0012669904,0.0013073232,0.002243484,0.000375068,0.000921668,0.0010219023,0.0014675432,0.014230704],"category_scores_gemma":[0.0004883582,0.00026591672,0.0006988188,0.0016696078,0.0005078546,0.0013624935,0.0009952527,0.0032421087,0.010379803],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000073058705,0.00012560212,0.000077330755,0.0069162813,0.000065536755,0.00031154638,0.000048924652,0.0002496184,0.0029829121,0.0064292187,0.083821796,0.8988982],"study_design_scores_gemma":[0.000029229122,0.000060928076,0.00017026035,0.0009187113,0.000025882482,0.0007092798,0.000013128079,0.000046169564,0.00023553405,0.0011723152,0.99661154,0.0000069998464],"about_ca_topic_score_codex":0.0011487505,"about_ca_topic_score_gemma":0.0031759916,"teacher_disagreement_score":0.014230704,"about_ca_system_score_codex":0.00073894695,"about_ca_system_score_gemma":0.0009426577,"threshold_uncertainty_score":0.04760641},"labels":[],"label_agreement":null},{"id":"W2006321561","doi":"10.1517/14728210903107751","title":"Emerging drugs for major depressive disorder","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Agomelatine; Antidepressant; Monoamine neurotransmitter; Medicine; Norepinephrine; Dopamine; Serotonin; Pharmacology; Duloxetine; Melatonin; Neuroscience; Psychiatry; Receptor; Internal medicine; Psychology; Anxiety","score_opus":0.03552954744009842,"score_gpt":0.38616203259610443,"score_spread":0.35063248515600604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006321561","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022011911,0.99108046,0.00045201703,0.0012301366,0.0008413327,0.00003209393,0.000048139245,0.000031522803,0.0060641416],"genre_scores_gemma":[0.0012604622,0.9896696,0.0012260915,0.001656062,0.00070951186,0.000037152335,0.0001083406,0.0000037999423,0.0053289672],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998313,0.000028952752,0.000022801669,0.00002644732,0.000074517855,0.00001601395],"domain_scores_gemma":[0.9998202,0.0000431464,0.00004261511,0.000006622384,0.00006176029,0.000025647274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041955212,0.0010061183,0.001201037,0.001281045,0.00029870195,0.0007035878,0.00075927214,0.0013475809,0.012196689],"category_scores_gemma":[0.00037799374,0.0002098899,0.0005453944,0.0010676988,0.0003031092,0.0009735253,0.0006009134,0.0017342444,0.009208265],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007931581,0.000111863454,0.00009942759,0.00803129,0.00006909509,0.00042621203,0.000036875284,0.00011160548,0.002990511,0.0025208697,0.06890443,0.91661847],"study_design_scores_gemma":[0.00007403309,0.00016152865,0.000596966,0.002025632,0.000091654445,0.0017852681,0.000033186938,0.00009512648,0.00046516993,0.0016559426,0.993004,0.0000115339235],"about_ca_topic_score_codex":0.0007762811,"about_ca_topic_score_gemma":0.002421856,"teacher_disagreement_score":0.012196689,"about_ca_system_score_codex":0.00049059873,"about_ca_system_score_gemma":0.000860979,"threshold_uncertainty_score":0.040802002},"labels":[],"label_agreement":null},{"id":"W2009384447","doi":"10.1517/14728214.2014.915025","title":"Emerging drugs for neuropathic pain","year":2014,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Pain Mechanisms and Treatments","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Queen's University","funders":"Canadian Institutes of Health Research; Wellcome Trust","keywords":"Medicine; Neuropathic pain; Gabapentin; Intensive care medicine; Pharmacology; Alternative medicine","score_opus":0.04484334409380448,"score_gpt":0.3797579390529872,"score_spread":0.33491459495918274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009384447","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000117190495,0.9959214,0.00023142704,0.00062102685,0.00047396004,0.000022614353,0.0000521951,0.000018680013,0.0025416524],"genre_scores_gemma":[0.0010097458,0.9957722,0.00036786916,0.0006467342,0.00026315407,0.000019173434,0.00008296027,0.0000027645062,0.0018353272],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99964213,0.000067923385,0.00004225515,0.00005270868,0.0001568869,0.0000380104],"domain_scores_gemma":[0.99966586,0.00012247518,0.00006866808,0.000013558995,0.00009972756,0.000029740442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006173062,0.0010713883,0.0014461756,0.0024708456,0.00028093028,0.0009966651,0.0008972039,0.0013957348,0.013918064],"category_scores_gemma":[0.0007585081,0.00022706804,0.0009237407,0.0019621975,0.00046226414,0.0012624778,0.00082687865,0.0023749843,0.0055674324],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000064723325,0.00005971913,0.00007677008,0.025700618,0.00013100854,0.00018338702,0.00005180231,0.0001968086,0.0017520362,0.00490494,0.04433853,0.92253965],"study_design_scores_gemma":[0.000035271805,0.00007768546,0.00039061776,0.006975525,0.00014011069,0.0009209502,0.000032328702,0.0000707766,0.0003735072,0.0020800873,0.9888896,0.00001357196],"about_ca_topic_score_codex":0.001114598,"about_ca_topic_score_gemma":0.0023131894,"teacher_disagreement_score":0.013918064,"about_ca_system_score_codex":0.00077637506,"about_ca_system_score_gemma":0.0014020563,"threshold_uncertainty_score":0.046560585},"labels":[],"label_agreement":null},{"id":"W2016233068","doi":"10.1517/14728214.2012.678833","title":"Emerging targets for the treatment of scleroderma","year":2012,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Systemic Sclerosis and Related Diseases","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Scleroderma (fungus); Disease; Personalized medicine; Immunology; Bioinformatics; Pathology","score_opus":0.10231439979693052,"score_gpt":0.39166777573168,"score_spread":0.28935337593474947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016233068","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014379535,0.9971431,0.00017895536,0.0005726435,0.00037171584,0.000010457618,0.000028886143,0.000012086994,0.0015383716],"genre_scores_gemma":[0.0010510174,0.9966468,0.0003309317,0.0005425753,0.0002819057,0.000014084858,0.00006790948,0.000002205008,0.0010625237],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997626,0.000051296756,0.000023737879,0.00003321983,0.000103528066,0.000025637974],"domain_scores_gemma":[0.99977225,0.00008046183,0.000042926236,0.0000074817754,0.000072925905,0.000023914115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049449434,0.0007714116,0.0012238612,0.0016808473,0.0002180875,0.0006676313,0.00067326816,0.0010562224,0.0058702566],"category_scores_gemma":[0.00050358346,0.00017265584,0.00058042654,0.0011884935,0.00034246824,0.0008614964,0.0005547101,0.0023021959,0.0034797597],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009549655,0.00009470876,0.00009741767,0.010513076,0.00009401207,0.00022992128,0.00003832723,0.00032845404,0.0027333517,0.0035251097,0.041616242,0.9406339],"study_design_scores_gemma":[0.00006890765,0.00014006483,0.000686431,0.0038788286,0.00009811963,0.0011939057,0.000041051862,0.00012671905,0.0006437817,0.0020311703,0.9910749,0.000016120848],"about_ca_topic_score_codex":0.00067598844,"about_ca_topic_score_gemma":0.0016732449,"teacher_disagreement_score":0.0058702566,"about_ca_system_score_codex":0.00047550633,"about_ca_system_score_gemma":0.0006728272,"threshold_uncertainty_score":0.019637942},"labels":[],"label_agreement":null},{"id":"W2018561236","doi":"10.1517/14728214.9.1.191","title":"Superbugs & Superdrugs: A Focus on Antibacterials – 6th Annual SMi Conference","year":2004,"lang":"en","type":"article","venue":"Expert Opinion on Emerging Drugs","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pyrogenesis (Canada)","funders":"","keywords":"Medicine; Cephalosporin; Antibiotics; Microbiology; Biology","score_opus":0.030020277683418035,"score_gpt":0.32962382828922154,"score_spread":0.2996035506058035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018561236","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023770291,0.25520292,0.04453808,0.12462217,0.14201611,0.0013131177,0.0021010912,0.0063414224,0.40009487],"genre_scores_gemma":[0.03009704,0.07359916,0.01513743,0.020328568,0.018056134,0.00061149313,0.0017727196,0.0007457404,0.83965176],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995364,0.000047507157,0.000015608544,0.000045856028,0.00025134927,0.00010332298],"domain_scores_gemma":[0.99947006,0.00007232478,0.000033876036,0.000017845066,0.00019040602,0.00021551417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015644669,0.001598783,0.00085986854,0.0013894273,0.00068442535,0.001883497,0.0009047204,0.0027800591,0.09344579],"category_scores_gemma":[0.00079196907,0.00052839174,0.0007927298,0.000602479,0.00038391346,0.0014692709,0.00096021924,0.0030459564,0.032700982],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003192996,0.0001548283,0.00010957894,0.00032224678,0.000020839821,0.00016055256,0.000016464664,0.00025091865,0.016700191,0.00190532,0.74116063,0.23887917],"study_design_scores_gemma":[0.000053149088,0.00023757061,0.00044681833,0.00006490962,0.000015980087,0.0003189824,0.000015365205,0.00058306253,0.008680725,0.0006638183,0.9889036,0.000016072923],"about_ca_topic_score_codex":0.00076300796,"about_ca_topic_score_gemma":0.002950166,"teacher_disagreement_score":0.09344579,"about_ca_system_score_codex":0.001126229,"about_ca_system_score_gemma":0.0010013011,"threshold_uncertainty_score":0.31260735},"labels":[],"label_agreement":null},{"id":"W2019078592","doi":"10.1517/14728210802568764","title":"Emerging tocolytics: challenges in designing and testing drugs to delay preterm delivery and prolong pregnancy","year":2008,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Preterm Birth and Chorioamnionitis","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Heritage Medical Research Clinic; University of Alberta","funders":"","keywords":"Medicine; Preterm delivery; Pregnancy; Intensive care medicine; Obstetrics; Pharmacology; Gestation","score_opus":0.08815268921509375,"score_gpt":0.3536720905677467,"score_spread":0.26551940135265295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019078592","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020230724,0.99581933,0.0004018413,0.0019500726,0.0003602907,0.000016704678,0.00002508827,0.000011749982,0.001212572],"genre_scores_gemma":[0.00085951976,0.9956291,0.0013639329,0.000948817,0.00035369815,0.000026525388,0.000036738315,0.0000026467155,0.0007791399],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99906546,0.00022617732,0.00013362596,0.00010040282,0.00041657605,0.000057707428],"domain_scores_gemma":[0.9979558,0.0009672647,0.00024541878,0.000046865618,0.0006852072,0.00009943219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002996314,0.0010620594,0.0033126415,0.0019042033,0.00040041195,0.0016256929,0.0019719612,0.0031011973,0.0033789787],"category_scores_gemma":[0.002614016,0.0004633779,0.00078556116,0.0019989633,0.00073723885,0.0030781224,0.0006388595,0.0026255795,0.0026523569],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010085599,0.00009587488,0.00018897554,0.015966352,0.000088679146,0.00042475277,0.00007869953,0.00040184864,0.001979799,0.0029574945,0.02837624,0.9493403],"study_design_scores_gemma":[0.00012158575,0.0003582932,0.0008947597,0.0094836,0.0002549484,0.001907615,0.00019746932,0.00036946594,0.0010823688,0.0034579642,0.9818308,0.000041044328],"about_ca_topic_score_codex":0.0020881728,"about_ca_topic_score_gemma":0.0051765637,"teacher_disagreement_score":0.0033789787,"about_ca_system_score_codex":0.0012005194,"about_ca_system_score_gemma":0.0026784854,"threshold_uncertainty_score":0.015846193},"labels":[],"label_agreement":null},{"id":"W2019398901","doi":"10.1517/14728214.11.2.217","title":"Emerging reverse transcriptase inhibitors for the treatment of HIV infection in adults","year":2006,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Medicine; Reverse transcriptase; Pharmacology; Nucleoside Reverse Transcriptase Inhibitor; Reverse-transcriptase inhibitor; Dosing; Drug; Regimen; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral load; Internal medicine; Biology; RNA","score_opus":0.03402692502663547,"score_gpt":0.3494930753719826,"score_spread":0.31546615034534714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019398901","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018290122,0.995793,0.00027226954,0.0003740803,0.00036667372,0.00002560055,0.000020857071,0.00001285511,0.002951727],"genre_scores_gemma":[0.00086789194,0.99488044,0.00075104844,0.0005122985,0.00031456145,0.000024601375,0.00006421788,0.0000023585346,0.0025826525],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99970156,0.00005048674,0.000029576378,0.000034775254,0.00015373324,0.000029819892],"domain_scores_gemma":[0.99974376,0.00008071362,0.000055986962,0.0000083728655,0.00007764129,0.000033494434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007714329,0.0011288454,0.0013356749,0.0019312246,0.0002719593,0.0005810853,0.00105898,0.0014477128,0.0063651656],"category_scores_gemma":[0.0005948478,0.00022463281,0.00057768164,0.001506018,0.00033634398,0.0009714895,0.0004493711,0.0016259484,0.0064447247],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007948337,0.000111607485,0.000118934106,0.007772375,0.000061039435,0.00032044694,0.000054293745,0.00012929102,0.0026964697,0.0012369368,0.029354725,0.95806444],"study_design_scores_gemma":[0.000080868405,0.00020849862,0.0008714843,0.0021696219,0.00009641719,0.002438862,0.0000407802,0.000066372704,0.0006779267,0.0008040489,0.99253243,0.000012568416],"about_ca_topic_score_codex":0.00084430847,"about_ca_topic_score_gemma":0.0024660819,"teacher_disagreement_score":0.0063651656,"about_ca_system_score_codex":0.00044433548,"about_ca_system_score_gemma":0.001046775,"threshold_uncertainty_score":0.02129364},"labels":[],"label_agreement":null},{"id":"W2025784617","doi":"10.1517/14728214.10.1.67","title":"The drug-based pipeline against restenosis","year":2005,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Coronary Interventions and Diagnostics","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute","funders":"","keywords":"Restenosis; Medicine; Drug; Conventional PCI; Sirolimus; Paclitaxel; Percutaneous coronary intervention; Intensive care medicine; Stent; Internal medicine; Cardiology; Pharmacology; Myocardial infarction; Chemotherapy","score_opus":0.05339832418767139,"score_gpt":0.3957091822183103,"score_spread":0.34231085803063893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025784617","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029001257,0.9953111,0.0002321672,0.0008623376,0.0003254566,0.0000100041025,0.00001858529,0.000018598002,0.0029318316],"genre_scores_gemma":[0.0012516082,0.99574465,0.0003552457,0.0005576205,0.00028379512,0.000010006885,0.00002921718,0.0000020206435,0.001765857],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997855,0.00004066667,0.000021334374,0.000028522127,0.00010402905,0.000019942952],"domain_scores_gemma":[0.9998117,0.00006367249,0.000032939926,0.0000062995077,0.000062761785,0.000022672897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070560497,0.0008075124,0.0012207051,0.0016500972,0.00029957466,0.0008116373,0.0006738182,0.0011862133,0.005567102],"category_scores_gemma":[0.0004810253,0.00020105131,0.00035379207,0.0013742206,0.00039569382,0.0012776502,0.00042981014,0.0014811539,0.0049614115],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000109960805,0.00014662607,0.00012318102,0.0061459057,0.000073885465,0.00028251787,0.000044698172,0.00021428274,0.00447893,0.0035706095,0.03685533,0.9479541],"study_design_scores_gemma":[0.00006959673,0.00022580588,0.0006427518,0.0014444191,0.00006772839,0.0009892548,0.000033019707,0.000084756306,0.0011038183,0.001567272,0.99376076,0.0000106756925],"about_ca_topic_score_codex":0.0007071172,"about_ca_topic_score_gemma":0.0019117713,"teacher_disagreement_score":0.005567102,"about_ca_system_score_codex":0.00054621167,"about_ca_system_score_gemma":0.0009143684,"threshold_uncertainty_score":0.018623829},"labels":[],"label_agreement":null},{"id":"W2026842455","doi":"10.1517/14728214.2012.667800","title":"Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome","year":2012,"lang":"en","type":"letter","venue":"Expert Opinion on Emerging Drugs","topic":"Respiratory Support and Mechanisms","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Centre; London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; ARDS; Intensive care medicine; Acute respiratory distress; Disease; Clinical trial; Psychological intervention; Lung; Internal medicine; Psychiatry","score_opus":0.02716428527604438,"score_gpt":0.33935478079536313,"score_spread":0.31219049551931877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026842455","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011347274,0.266145,0.0014043705,0.6380606,0.079686314,0.00010057398,0.00010864131,0.00010290632,0.0132568255],"genre_scores_gemma":[0.015512922,0.26234818,0.0036368032,0.5229661,0.1716531,0.00022989973,0.00014453757,0.000047799767,0.02346061],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988814,0.000323598,0.00014736204,0.00015208694,0.00040080026,0.00009467558],"domain_scores_gemma":[0.99830663,0.00095243944,0.0001585479,0.0000531305,0.0003966025,0.00013261127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012600751,0.0007870739,0.0013662194,0.00061045645,0.00090073154,0.0013979019,0.0009802749,0.011969661,0.0048526553],"category_scores_gemma":[0.0045037,0.00028428124,0.0008773191,0.00047932283,0.0013849502,0.0021459188,0.0007690533,0.0142830005,0.0071841604],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034414956,0.00017747364,0.00051452965,0.0014668523,0.00006638305,0.008011828,0.00013387357,0.00029629745,0.002569407,0.010519303,0.7317446,0.2441553],"study_design_scores_gemma":[0.00023003892,0.00019919491,0.0005337493,0.00054970686,0.000036935693,0.0061912457,0.00007596746,0.0003077427,0.0005958615,0.0072318586,0.98401976,0.000027883902],"about_ca_topic_score_codex":0.00046856632,"about_ca_topic_score_gemma":0.0016614649,"teacher_disagreement_score":0.011969661,"about_ca_system_score_codex":0.0016114517,"about_ca_system_score_gemma":0.0009517351,"threshold_uncertainty_score":0.016233742},"labels":[],"label_agreement":null},{"id":"W2026959104","doi":"10.1517/14728214.2014.882316","title":"Emerging drugs for cystic fibrosis","year":2014,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Cystic Fibrosis Research Advances","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Cystic fibrosis; Medicine; Cystic fibrosis transmembrane conductance regulator; Disease; Regulator; Genetic enhancement; Bioinformatics; Pathology; Internal medicine; Gene; Genetics; Biology","score_opus":0.03955102766984114,"score_gpt":0.4120936363719128,"score_spread":0.3725426087020717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026959104","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024888504,0.9824834,0.0005056037,0.0025743295,0.002264321,0.000052306437,0.00019621696,0.00007444601,0.011600492],"genre_scores_gemma":[0.0018533545,0.9805855,0.0008760327,0.002714809,0.00096059893,0.000048780654,0.00037093012,0.000010748982,0.012579329],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997049,0.00004869496,0.000025783116,0.000043977383,0.00014258186,0.000034146753],"domain_scores_gemma":[0.99974173,0.000072398616,0.000042103235,0.000012603487,0.00008742983,0.00004365582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004887373,0.0008428764,0.0008820237,0.0018913182,0.00033607698,0.0008582576,0.0008272203,0.0015754034,0.022711698],"category_scores_gemma":[0.0007015507,0.00019645276,0.0007833473,0.0011205935,0.00036463505,0.0011200956,0.0009441121,0.0028374526,0.012850511],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006242281,0.000063787505,0.00007386387,0.006455114,0.000051197298,0.00019582985,0.000041370306,0.00013964437,0.0020562366,0.0056998814,0.12619741,0.8589633],"study_design_scores_gemma":[0.000021200398,0.000038726008,0.00014533316,0.0010997815,0.000022080738,0.0004165938,0.000009958417,0.000032716416,0.00018223142,0.0009765436,0.9970493,0.0000055412825],"about_ca_topic_score_codex":0.0010182201,"about_ca_topic_score_gemma":0.0027828075,"teacher_disagreement_score":0.022711698,"about_ca_system_score_codex":0.00067426986,"about_ca_system_score_gemma":0.0011376945,"threshold_uncertainty_score":0.07597816},"labels":[],"label_agreement":null},{"id":"W2035771416","doi":"10.1517/14728214.13.1.63","title":"Emerging drugs for spinal cord injury","year":2008,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Spinal Cord Injury Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Krembil Foundation; University of Toronto; Toronto Western Hospital","funders":"","keywords":"Medicine; Neuroprotection; Clinical trial; Spinal cord injury; Neuroscience; Bioinformatics; Intensive care medicine; Pharmacology; Spinal cord; Pathology; Biology","score_opus":0.12311867835735468,"score_gpt":0.4933757197572663,"score_spread":0.3702570413999116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035771416","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021763983,0.99290484,0.0003502734,0.0009428173,0.0006204689,0.000032290984,0.000037825976,0.000024447123,0.0048693805],"genre_scores_gemma":[0.001302859,0.99182886,0.0009817539,0.0008373652,0.00043650015,0.00004368412,0.00008947693,0.0000034723796,0.0044760043],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997706,0.00003809476,0.000027133909,0.00003214362,0.000106924716,0.000025050074],"domain_scores_gemma":[0.99980944,0.000046676978,0.00003992939,0.000009445357,0.000070160786,0.000024365949],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050117786,0.001222823,0.0012756311,0.0022682531,0.00035309172,0.0009809223,0.00078681484,0.0016283806,0.013753066],"category_scores_gemma":[0.00039419098,0.0002442165,0.0005766406,0.0015906375,0.00042311146,0.0013735495,0.00076922216,0.0021344544,0.008416116],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000082620885,0.00013530579,0.00008230647,0.009964576,0.00007889073,0.00041102426,0.00006198012,0.00020220404,0.00490337,0.00599844,0.041236408,0.93684274],"study_design_scores_gemma":[0.00005575743,0.00013421128,0.0003334298,0.0021035483,0.000068311005,0.0011973301,0.000035592173,0.00007623675,0.0008197864,0.0021792455,0.9929853,0.00001112107],"about_ca_topic_score_codex":0.0009871183,"about_ca_topic_score_gemma":0.0023487424,"teacher_disagreement_score":0.013753066,"about_ca_system_score_codex":0.000696016,"about_ca_system_score_gemma":0.0014381497,"threshold_uncertainty_score":0.046008587},"labels":[],"label_agreement":null},{"id":"W2035774269","doi":"10.1517/14728214.8.2.297","title":"Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae","year":2003,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Pneumonia and Respiratory Infections","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre","funders":"","keywords":"Telithromycin; Ketolide; Streptococcus pneumoniae; Microbiology; Macrolide Antibiotics; Efflux; Erythromycin; Medicine; Antibiotics; Biology","score_opus":0.11605327297256299,"score_gpt":0.4387001288850574,"score_spread":0.3226468559124944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035774269","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029274795,0.9977487,0.00019705255,0.00035470002,0.00018214148,0.0000092223645,0.000016393891,0.000013379474,0.001185622],"genre_scores_gemma":[0.001182672,0.9959616,0.00047801633,0.00045354138,0.00023389418,0.000014259734,0.00005578558,0.0000021613632,0.0016180957],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998319,0.000031292366,0.000022221395,0.000031704196,0.000066801564,0.000016101678],"domain_scores_gemma":[0.9998361,0.000045032022,0.000034202538,0.0000061712963,0.000052236464,0.000026313428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041563818,0.00083266484,0.0013036168,0.0015361111,0.00026095184,0.00068570336,0.0006501411,0.0012074738,0.0043267175],"category_scores_gemma":[0.00033074216,0.00019166726,0.00038497354,0.0016314487,0.00029341536,0.001193804,0.00038324064,0.0010973922,0.003278413],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012631073,0.000093903756,0.00014920458,0.007743575,0.00006186461,0.00035417828,0.000036999398,0.0001753363,0.0028239468,0.0008562165,0.021435795,0.96614265],"study_design_scores_gemma":[0.00011152726,0.00036674165,0.0015575873,0.001986115,0.00015229553,0.003402035,0.000069517824,0.00013955966,0.0009546048,0.0008849173,0.9903571,0.00001803543],"about_ca_topic_score_codex":0.0008370612,"about_ca_topic_score_gemma":0.002480098,"teacher_disagreement_score":0.0043267175,"about_ca_system_score_codex":0.00040610533,"about_ca_system_score_gemma":0.0008114277,"threshold_uncertainty_score":0.014474332},"labels":[],"label_agreement":null},{"id":"W2040792648","doi":"10.1517/14728214.13.1.81","title":"Emerging drugs for malignant glioma","year":2008,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Glioma; Temozolomide; Radiation therapy; Oncology; Glioblastoma; Chemotherapy; Targeted therapy; Internal medicine; Cancer; Cancer research","score_opus":0.05204084896289074,"score_gpt":0.3800900213728202,"score_spread":0.3280491724099295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040792648","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020926933,0.9950211,0.00027963513,0.00070601,0.00041444064,0.000019488429,0.00003084463,0.000017455957,0.003301785],"genre_scores_gemma":[0.0010481738,0.99528426,0.00052846916,0.0006168842,0.00028867746,0.000017984552,0.000069718255,0.000002624195,0.0021432086],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99973756,0.000046319197,0.000030733652,0.00003990551,0.00012080567,0.00002458486],"domain_scores_gemma":[0.9998023,0.00006106319,0.000042675714,0.0000088708875,0.000063938045,0.000021285472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005108553,0.0010205178,0.0013287587,0.002500846,0.00030738444,0.0008984177,0.00073041813,0.0013503098,0.0070712133],"category_scores_gemma":[0.00046756977,0.0002277163,0.0007315323,0.0017259109,0.00042228986,0.001238103,0.00065784424,0.0018883708,0.0052676015],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006709728,0.000085180196,0.00012691278,0.011077509,0.00009063191,0.00055747,0.00006619204,0.00023488296,0.003434876,0.004059072,0.04737982,0.93282044],"study_design_scores_gemma":[0.000041111,0.00008784552,0.00036698364,0.0021923066,0.000071146176,0.0021411777,0.000030446976,0.00008505069,0.00065887603,0.0016144981,0.99269956,0.000011111298],"about_ca_topic_score_codex":0.0010053335,"about_ca_topic_score_gemma":0.0023713063,"teacher_disagreement_score":0.0070712133,"about_ca_system_score_codex":0.00078397576,"about_ca_system_score_gemma":0.001030786,"threshold_uncertainty_score":0.023655593},"labels":[],"label_agreement":null},{"id":"W2067328075","doi":"10.1517/14728210903203790","title":"Antigen-specific therapies in multiple sclerosis","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal Neurological Institute and Hospital","funders":"","keywords":"Medicine; Multiple sclerosis; Effector; Antigen; Immunology; Immune system; Neuroscience; Biology","score_opus":0.2141295040898592,"score_gpt":0.40577077165303077,"score_spread":0.19164126756317157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067328075","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007164074,0.9983082,0.00010388396,0.00035391722,0.0002532771,0.0000067202855,0.0000056566787,0.0000059238137,0.00089079083],"genre_scores_gemma":[0.00051936356,0.9982981,0.00021780515,0.00024680604,0.00023342448,0.000007896814,0.000010359033,7.8212975e-7,0.00046551207],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99971896,0.000073051895,0.000037135113,0.000030061175,0.00012130029,0.00001945081],"domain_scores_gemma":[0.9997371,0.00012002462,0.000046411944,0.000010406127,0.00006313583,0.000022995853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009282261,0.00074935355,0.00124629,0.0018620171,0.0002838736,0.0006332742,0.00077937124,0.0014183148,0.0035327745],"category_scores_gemma":[0.0006330295,0.00019298725,0.00040469068,0.0016891226,0.00057036604,0.0011485087,0.00051756366,0.0016160158,0.002736398],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009180074,0.00011983001,0.0001016379,0.01572004,0.00008023782,0.00041790554,0.0000616431,0.00037411612,0.0027599013,0.00463492,0.038074277,0.9375638],"study_design_scores_gemma":[0.000053693653,0.00017443976,0.00060261664,0.004604336,0.00008736227,0.002459534,0.00006054583,0.000096437456,0.0006844204,0.0035325347,0.98762846,0.00001576056],"about_ca_topic_score_codex":0.00082551513,"about_ca_topic_score_gemma":0.0015046033,"teacher_disagreement_score":0.0035327745,"about_ca_system_score_codex":0.00063864,"about_ca_system_score_gemma":0.0010928129,"threshold_uncertainty_score":0.01181829},"labels":[],"label_agreement":null},{"id":"W2068824007","doi":"10.1517/14728214.2013.801453","title":"Emerging anti-inflammatory drugs for atherosclerosis","year":2013,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Atherosclerosis and Cardiovascular Diseases","field":"Immunology and Microbiology","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Heart and Stroke Foundation; University of Toronto","funders":"","keywords":"Medicine; Inflammation; Intensive care medicine; Pharmacology; Internal medicine","score_opus":0.03811104574974039,"score_gpt":0.32115478340998305,"score_spread":0.28304373766024266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068824007","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013545311,0.9946407,0.0002912283,0.0009110272,0.0009771598,0.000020679627,0.00004458356,0.000024540434,0.0029547121],"genre_scores_gemma":[0.0010376107,0.99383485,0.0005116564,0.0008664144,0.00069654355,0.000021039668,0.000092007554,0.000004208118,0.0029356147],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996855,0.000052498464,0.00003404152,0.000044893095,0.00014990332,0.000033113458],"domain_scores_gemma":[0.99964845,0.00009351423,0.00006280572,0.00001411392,0.00013962152,0.000041420262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006157362,0.0010104693,0.0012800797,0.0020133818,0.00029813746,0.0009288653,0.0008272818,0.0013764297,0.009804867],"category_scores_gemma":[0.00070648134,0.00023946026,0.0006412673,0.0016993071,0.0004343435,0.0012566246,0.0007284349,0.0027026166,0.007408818],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007334126,0.00007989299,0.00009169302,0.009789454,0.00007195441,0.0002115701,0.00003821973,0.00020019367,0.0026431766,0.0034710385,0.07578341,0.90754604],"study_design_scores_gemma":[0.000025347888,0.000062988234,0.0002719391,0.0017736083,0.000048136895,0.0007094247,0.000016614136,0.0000605077,0.00033361252,0.0010578539,0.9956304,0.000009651005],"about_ca_topic_score_codex":0.0007608573,"about_ca_topic_score_gemma":0.0017162291,"teacher_disagreement_score":0.009804867,"about_ca_system_score_codex":0.00065432483,"about_ca_system_score_gemma":0.0010780026,"threshold_uncertainty_score":0.032800555},"labels":[],"label_agreement":null},{"id":"W2075748215","doi":"10.1517/14728214.2015.985204","title":"Emerging drugs for celiac disease","year":2014,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Celiac Disease Research and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Disease; Intensive care medicine; Internal medicine","score_opus":0.04708593854982716,"score_gpt":0.4214706061184548,"score_spread":0.37438466756862765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075748215","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000847874,0.99561596,0.00011418373,0.0011478352,0.0007247844,0.000015002492,0.00004057872,0.000012646781,0.0022442571],"genre_scores_gemma":[0.0008340736,0.9957948,0.00023399176,0.0010769654,0.00044718565,0.0000142908875,0.000073236675,0.0000019695065,0.0015235373],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996749,0.00007011128,0.00004344562,0.000045936184,0.0001350106,0.000030506388],"domain_scores_gemma":[0.99959046,0.00015191082,0.00008704167,0.000012950588,0.00012313123,0.000034606313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060499215,0.00074251357,0.0012109298,0.0021351206,0.00023076532,0.0009569388,0.000829228,0.0015405883,0.013352032],"category_scores_gemma":[0.0009211645,0.00019572713,0.00086771883,0.0016383905,0.00036600447,0.0010395448,0.0006546879,0.002216003,0.0054440987],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007178236,0.000048665937,0.00009061325,0.027942646,0.00014199536,0.00019732387,0.000050917726,0.00012140446,0.0011622834,0.003581582,0.071306095,0.8952847],"study_design_scores_gemma":[0.000039011033,0.000055338834,0.00035836783,0.007833761,0.00013251518,0.0008423146,0.000029006635,0.00004651224,0.0001823167,0.0012912466,0.9891802,0.000009455935],"about_ca_topic_score_codex":0.0010422191,"about_ca_topic_score_gemma":0.0022620747,"teacher_disagreement_score":0.013352032,"about_ca_system_score_codex":0.00071694463,"about_ca_system_score_gemma":0.0012140624,"threshold_uncertainty_score":0.044667006},"labels":[],"label_agreement":null},{"id":"W2085013428","doi":"10.1517/14728214.13.2.363","title":"Emerging antidyslipidemic drugs","year":2008,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"","keywords":"Medicine; Ezetimibe; Tolerability; Adverse effect; Intensive care medicine; Coronary heart disease; Niacin; Pharmacology; Statin; Internal medicine","score_opus":0.04300957262493703,"score_gpt":0.3725274129698519,"score_spread":0.3295178403449149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085013428","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025065363,0.99721116,0.00018624206,0.00037115,0.00020843884,0.0000069396638,0.000015835814,0.000010202804,0.0017394804],"genre_scores_gemma":[0.0010784589,0.9967693,0.00041501736,0.00037536933,0.0002348083,0.000008863778,0.00003855585,0.000001257055,0.0010783412],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997286,0.000044792392,0.000034987166,0.000045208588,0.000121689154,0.000024620913],"domain_scores_gemma":[0.99969995,0.00010400022,0.000054299784,0.000008552186,0.00010320358,0.00002996552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006655783,0.00085065654,0.0013749178,0.0020080511,0.00020692893,0.0007304535,0.00082174677,0.0010130448,0.0042587584],"category_scores_gemma":[0.0005776897,0.0002098891,0.00042185848,0.0017586356,0.0003063164,0.0010723093,0.00043348002,0.0011528054,0.0024786133],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009040349,0.00007885147,0.00026069334,0.010078855,0.00009034953,0.00038923908,0.00003601837,0.00025362024,0.0019826398,0.002103059,0.021822225,0.96281403],"study_design_scores_gemma":[0.00007952262,0.00020124875,0.0015563525,0.0043554152,0.00020919555,0.0029201962,0.00007298916,0.0002368598,0.0010231577,0.0018036691,0.9875238,0.000017501685],"about_ca_topic_score_codex":0.00090401934,"about_ca_topic_score_gemma":0.0020432721,"teacher_disagreement_score":0.0042587584,"about_ca_system_score_codex":0.0005541381,"about_ca_system_score_gemma":0.0010856129,"threshold_uncertainty_score":0.014246941},"labels":[],"label_agreement":null},{"id":"W2091075249","doi":"10.1517/14728214.12.3.367","title":"Pharmacologic therapeutics for cardiac reperfusion injury","year":2007,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Cardiac Ischemia and Reperfusion","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; National Institutes of Health; University of Lethbridge","keywords":"Medicine; Mitochondrial permeability transition pore; Cardioprotection; Reperfusion injury; Pharmacology; Bradykinin; Potassium channel; Myocardial infarction; Receptor; Ischemia; Internal medicine; Programmed cell death; Biochemistry; Chemistry; Apoptosis","score_opus":0.08498793500887913,"score_gpt":0.44869112029704383,"score_spread":0.3637031852881647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091075249","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00034581812,0.99323314,0.00035460858,0.0006498347,0.00052559684,0.000026751144,0.000026633414,0.00002287167,0.0048146117],"genre_scores_gemma":[0.0012763316,0.9942116,0.0006736769,0.0005976168,0.0003777529,0.000027154007,0.000055831297,0.0000033474219,0.0027766472],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99977654,0.00003728513,0.000026893224,0.000029459121,0.000108540116,0.000021234035],"domain_scores_gemma":[0.9998324,0.00005819602,0.000031649834,0.0000094109655,0.00004932762,0.00001887423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005690166,0.0009995579,0.0014960933,0.0020522205,0.00036163226,0.0008041231,0.0008928176,0.0013202237,0.0075693917],"category_scores_gemma":[0.00042246844,0.00022264614,0.00056320865,0.0014540816,0.00045310386,0.0011254916,0.0005260349,0.0021829656,0.005643217],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009765532,0.0002069237,0.00009463516,0.006744151,0.00007205556,0.00046037495,0.000058153208,0.00019226603,0.004624921,0.003987161,0.034710567,0.94875103],"study_design_scores_gemma":[0.00008151885,0.00020648721,0.0005687566,0.0013633252,0.00007445373,0.0021223766,0.000034315788,0.00009218199,0.0009005205,0.0016425038,0.9928999,0.0000137252355],"about_ca_topic_score_codex":0.00054486725,"about_ca_topic_score_gemma":0.0014694325,"teacher_disagreement_score":0.0075693917,"about_ca_system_score_codex":0.00054724555,"about_ca_system_score_gemma":0.00073141936,"threshold_uncertainty_score":0.025322199},"labels":[],"label_agreement":null},{"id":"W2092130790","doi":"10.1517/14728214.2010.517746","title":"Emerging therapies for cystic fibrosis lung disease","year":2010,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Cystic Fibrosis Research Advances","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; SickKids Foundation; University of Toronto","funders":"","keywords":"Cystic fibrosis; Mucociliary clearance; Medicine; Chloride channel; Airway; Lung; Cystic fibrosis transmembrane conductance regulator; Fibrosis; Respiratory system; Lung disease; Ion channel; Pathology; Internal medicine; Receptor; Cell biology; Anesthesia; Biology","score_opus":0.03499504691110344,"score_gpt":0.4096748499475913,"score_spread":0.37467980303648785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092130790","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013525705,0.9944465,0.0002742585,0.0012228033,0.00083848136,0.000014469114,0.00002251193,0.000016773954,0.0030289849],"genre_scores_gemma":[0.00069096836,0.99460185,0.0006370457,0.0009505365,0.0005553546,0.000017243874,0.00004718218,0.0000028309955,0.002497085],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997491,0.00004554177,0.000024129704,0.000031153966,0.00012881315,0.000021262389],"domain_scores_gemma":[0.99977356,0.000082666564,0.00003034568,0.000009284267,0.00007478707,0.000029276456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006029705,0.0009589868,0.0011292945,0.001640836,0.00031367416,0.00070969446,0.000687138,0.0015008437,0.007544317],"category_scores_gemma":[0.000534239,0.00017775751,0.00051444734,0.0011653661,0.00042728387,0.0013435641,0.000683252,0.002572661,0.004998344],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000691015,0.00010053672,0.00009621015,0.0073797456,0.000065815104,0.00034116927,0.000065476415,0.00023336061,0.0032816576,0.0051353443,0.07592572,0.9073059],"study_design_scores_gemma":[0.00003196561,0.00007434098,0.0003321272,0.0018200102,0.000044470173,0.00094460964,0.000036278816,0.00006274794,0.00032181907,0.0017863176,0.9945363,0.000009151176],"about_ca_topic_score_codex":0.00067676225,"about_ca_topic_score_gemma":0.0016427969,"teacher_disagreement_score":0.007544317,"about_ca_system_score_codex":0.000623774,"about_ca_system_score_gemma":0.0008739209,"threshold_uncertainty_score":0.025238216},"labels":[],"label_agreement":null},{"id":"W2122042922","doi":"10.1517/14728214.2012.681301","title":"Emerging drugs for major depressive disorder: an update","year":2012,"lang":"en","type":"editorial","venue":"Expert Opinion on Emerging Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Major depressive disorder; Psychiatry; Pharmacology; Mood","score_opus":0.013876679629682066,"score_gpt":0.33894847378183945,"score_spread":0.32507179415215737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122042922","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021274512,0.3616448,0.0005129258,0.046323862,0.5876976,0.00004551555,0.00011576606,0.00008029793,0.0033664345],"genre_scores_gemma":[0.0015165911,0.29574722,0.0008743595,0.048066206,0.6439891,0.000048822694,0.000119821176,0.00003288076,0.0096050305],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984302,0.00031965636,0.0003242734,0.00013876085,0.0006680971,0.00011909981],"domain_scores_gemma":[0.99447507,0.0024785006,0.0005608266,0.00010334474,0.0018896319,0.00049259077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038157334,0.0022312074,0.0029888733,0.0022358787,0.00085772533,0.002443309,0.0020269426,0.006651577,0.0043745604],"category_scores_gemma":[0.0063792225,0.00058325176,0.001676829,0.0012770188,0.00096182805,0.002968923,0.00083314016,0.009107791,0.002941695],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015386211,0.00004194563,0.000067780245,0.0021582507,0.000111088106,0.00034321347,0.000021486978,0.000054424898,0.00022417681,0.00050608517,0.91654754,0.07977007],"study_design_scores_gemma":[0.00020229803,0.0001168394,0.00031776694,0.0016675214,0.0002819846,0.00080819067,0.000031831365,0.00013270686,0.000120297234,0.00052704616,0.9957749,0.000018592302],"about_ca_topic_score_codex":0.0010835386,"about_ca_topic_score_gemma":0.0046634446,"teacher_disagreement_score":0.006651577,"about_ca_system_score_codex":0.001373023,"about_ca_system_score_gemma":0.0018456365,"threshold_uncertainty_score":0.020179808},"labels":[],"label_agreement":null},{"id":"W2127246176","doi":"10.1517/14728214.12.1.113","title":"Emerging drugs in neuropathic pain","year":2007,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Pain Mechanisms and Treatments","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Queen's University","funders":"Canadian Institutes of Health Research; Pfizer","keywords":"Medicine; Neuropathic pain; Pharmacology; Chronic pain; Adverse effect; Clinical trial; Population; Intensive care medicine; Bioinformatics; Psychiatry; Internal medicine","score_opus":0.05585911933335879,"score_gpt":0.39008517709162505,"score_spread":0.33422605775826625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127246176","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000150934,0.995133,0.00026264205,0.00062810676,0.00064713776,0.0000141392575,0.000014537451,0.00001176365,0.0031376842],"genre_scores_gemma":[0.00080930133,0.9946308,0.00058126304,0.0008948343,0.000622986,0.000016860564,0.000037297013,0.0000025507356,0.0024041124],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99957424,0.000079233454,0.000045333447,0.00006781748,0.00019431747,0.00003906929],"domain_scores_gemma":[0.99953604,0.00018214318,0.00006675123,0.000023652648,0.00014160332,0.000049901377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010152144,0.001290359,0.001847279,0.0030740441,0.0004522859,0.0012146501,0.0011391785,0.002255159,0.008894423],"category_scores_gemma":[0.00069513003,0.00032940856,0.0006790183,0.0032380756,0.0008157176,0.0024784494,0.0008571045,0.003018766,0.0063047856],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007605679,0.0001316212,0.00012858628,0.009295185,0.00005911188,0.000543577,0.000083783365,0.00027479653,0.0026557334,0.006999401,0.039155178,0.940597],"study_design_scores_gemma":[0.000036701884,0.0001110438,0.0004080041,0.0016317775,0.0000399112,0.0017177287,0.00004853754,0.000081018865,0.00049419096,0.0025185402,0.9928988,0.000013754742],"about_ca_topic_score_codex":0.0010745191,"about_ca_topic_score_gemma":0.002712932,"teacher_disagreement_score":0.008894423,"about_ca_system_score_codex":0.00097391254,"about_ca_system_score_gemma":0.0012600656,"threshold_uncertainty_score":0.029754758},"labels":[],"label_agreement":null},{"id":"W2140016150","doi":"10.1517/14728214.2015.1050376","title":"Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials","year":2015,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health","funders":"","keywords":"Tardive dyskinesia; Neurochemical; Dopamine; Medicine; Dopamine receptor D2; Pharmacology; Antipsychotic; Monoamine neurotransmitter; Dyskinesia; Neuroscience; Dopamine receptor; Schizophrenia (object-oriented programming); Serotonin; Internal medicine; Receptor; Psychology; Psychiatry; Parkinson's disease","score_opus":0.2655091623101564,"score_gpt":0.5465815142672025,"score_spread":0.28107235195704605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140016150","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00095503975,0.9936087,0.00036146538,0.0009826294,0.00044481718,0.00021384715,0.00026058813,0.000029175146,0.0031438188],"genre_scores_gemma":[0.0058453074,0.98846895,0.0010171469,0.0019097668,0.00029470207,0.0002901724,0.0003536784,0.000010181361,0.0018100321],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996903,0.00008951607,0.000051806735,0.000038587677,0.000094532115,0.000035242203],"domain_scores_gemma":[0.999244,0.0002432862,0.00023005159,0.00001831428,0.00019094897,0.00007348607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014976477,0.000840251,0.0019731817,0.0007976218,0.0001755908,0.0010016265,0.0010767617,0.0013456483,0.0085910885],"category_scores_gemma":[0.0014326607,0.00019743128,0.0014940469,0.0008971141,0.00032337112,0.00075090805,0.0004388263,0.0016198594,0.0019112761],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016524247,0.00038092837,0.00023544928,0.05668103,0.00059503264,0.00022313416,0.00006492261,0.00039399797,0.0034838773,0.0023179026,0.0455579,0.88841337],"study_design_scores_gemma":[0.005358131,0.004146615,0.0028926407,0.0625606,0.0031387652,0.0015637354,0.000150252,0.0006024392,0.0025158878,0.0034732663,0.9135175,0.0000802182],"about_ca_topic_score_codex":0.00085523794,"about_ca_topic_score_gemma":0.0028216213,"teacher_disagreement_score":0.0085910885,"about_ca_system_score_codex":0.0006262936,"about_ca_system_score_gemma":0.0016833345,"threshold_uncertainty_score":0.028740048},"labels":[],"label_agreement":null},{"id":"W2144409780","doi":"10.1517/14728214.6.2.281","title":"Pharmacological treatment for prevention of restenosis","year":2001,"lang":"en","type":"article","venue":"Expert Opinion on Emerging Drugs","topic":"Coronary Interventions and Diagnostics","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"Pfizer","keywords":"Restenosis; Medicine; Intimal hyperplasia; Neointimal hyperplasia; Cardiology; Angioplasty; Coronary artery disease; Conventional PCI; Internal medicine; Percutaneous coronary intervention; Neointima; Interventional cardiology; Stent; Myocardial infarction; Smooth muscle","score_opus":0.08141778822303335,"score_gpt":0.4207583856965823,"score_spread":0.33934059747354894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144409780","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000836146,0.9874808,0.0010744537,0.00398554,0.0012325611,0.000045096644,0.0001062494,0.000055215427,0.005183914],"genre_scores_gemma":[0.0074010813,0.9820057,0.0012836693,0.0030039984,0.001955418,0.000071126844,0.00021444474,0.000013480735,0.004051094],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999671,0.00008190462,0.000038552946,0.000049226193,0.00012552273,0.000033815733],"domain_scores_gemma":[0.9997631,0.000077466764,0.000050107923,0.000008575896,0.00007991149,0.000020867143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000422668,0.0005432672,0.0009187453,0.00085536303,0.00021121609,0.0007337344,0.0006512288,0.0013121808,0.0072634555],"category_scores_gemma":[0.00056880055,0.00011494872,0.0005773008,0.0003681252,0.0003150597,0.0006196491,0.00043858,0.00214441,0.0037457482],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031890091,0.00038288883,0.00029838784,0.010942714,0.00021011752,0.00042214987,0.00005710696,0.00019583371,0.010174224,0.0055500926,0.0631907,0.9082569],"study_design_scores_gemma":[0.00025295976,0.0007309308,0.0020289351,0.003364744,0.00026301167,0.0017425398,0.000055956618,0.0002580643,0.0026077891,0.0031646818,0.98549855,0.000031918833],"about_ca_topic_score_codex":0.00040842936,"about_ca_topic_score_gemma":0.0009311536,"teacher_disagreement_score":0.0072634555,"about_ca_system_score_codex":0.0004048416,"about_ca_system_score_gemma":0.0004575747,"threshold_uncertainty_score":0.024298668},"labels":[],"label_agreement":null},{"id":"W2147313898","doi":"10.1517/14728214.9.2.223","title":"Use of cytokines in infection","year":2004,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Hepatitis C virus research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"","keywords":"Immune system; Immunology; Medicine; Adjuvant; Cytokine; Antimicrobial; Antibiotics; Vaccination; Infectious disease (medical specialty); Proinflammatory cytokine; Disease; Biology; Inflammation; Microbiology; Internal medicine","score_opus":0.1613996187446005,"score_gpt":0.4539644417797895,"score_spread":0.29256482303518905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147313898","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019525585,0.9978527,0.00015655335,0.00021823075,0.00030444088,0.0000052433975,0.0000060132247,0.000006297534,0.0012552625],"genre_scores_gemma":[0.0016217574,0.9959044,0.00033743161,0.00032906662,0.00037625234,0.000014236861,0.000017590863,0.0000020078312,0.0013971906],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996836,0.00006882561,0.000041608273,0.000056021403,0.00012349174,0.000026535647],"domain_scores_gemma":[0.99978226,0.000101719925,0.000036212467,0.000011432288,0.000048840302,0.000019520301],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059608417,0.00096003356,0.0013407398,0.0016873891,0.00033039862,0.0010347349,0.0006382902,0.0013179077,0.0031557397],"category_scores_gemma":[0.00047219187,0.00024661535,0.00045397587,0.0012999257,0.000623197,0.0012031754,0.0006081895,0.0016604087,0.0029570297],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001834585,0.000094539064,0.00024319951,0.010882325,0.0000615499,0.00060506875,0.00013114314,0.00026276684,0.010919531,0.004557524,0.018704297,0.9533546],"study_design_scores_gemma":[0.00004604064,0.00017762075,0.0006679082,0.0017911486,0.00006377837,0.0026211822,0.000054910797,0.00006522815,0.0035091839,0.00157148,0.98941785,0.000013613273],"about_ca_topic_score_codex":0.00060266076,"about_ca_topic_score_gemma":0.0008033396,"teacher_disagreement_score":0.0031557397,"about_ca_system_score_codex":0.0006251748,"about_ca_system_score_gemma":0.00076497404,"threshold_uncertainty_score":0.010556996},"labels":[],"label_agreement":null},{"id":"W2335279309","doi":"10.1517/14728214.2016.1170117","title":"Emerging drugs for graft-versus-host disease","year":2016,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Disease; Clinical trial; Graft-versus-host disease; Immunology; Intensive care medicine; Internal medicine","score_opus":0.054858529043226835,"score_gpt":0.39320863521173127,"score_spread":0.3383501061685044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2335279309","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009282311,0.9966202,0.00013702636,0.0007157886,0.000505626,0.000010061963,0.000034355195,0.000011168007,0.0018729132],"genre_scores_gemma":[0.0006750108,0.9969771,0.00020678478,0.0006385893,0.00029284565,0.000010109646,0.00005787872,0.000002070873,0.0011396289],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997271,0.000054328397,0.0000344813,0.000039495433,0.00011699567,0.000027674918],"domain_scores_gemma":[0.9996604,0.00013279135,0.00006655794,0.0000094977795,0.00010424206,0.000026396112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000500619,0.0007926528,0.0012035411,0.0016490247,0.00022793243,0.00081023213,0.0007740618,0.0011362777,0.008713073],"category_scores_gemma":[0.000743637,0.00015844105,0.0007110948,0.0012510087,0.0003370532,0.001075134,0.0005734354,0.0021101567,0.003684226],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006527282,0.00004687077,0.00008257783,0.016694311,0.000116650146,0.00017371774,0.000040231254,0.0002605545,0.0012250046,0.0033948477,0.06130976,0.9165902],"study_design_scores_gemma":[0.000021115455,0.000051833737,0.00026283084,0.0049029286,0.000103483406,0.00080689974,0.00002363714,0.000066865156,0.00022086567,0.0013718159,0.9921589,0.000008875525],"about_ca_topic_score_codex":0.0007207106,"about_ca_topic_score_gemma":0.0016127609,"teacher_disagreement_score":0.008713073,"about_ca_system_score_codex":0.0006269245,"about_ca_system_score_gemma":0.001029467,"threshold_uncertainty_score":0.029148102},"labels":[],"label_agreement":null},{"id":"W2548436673","doi":"10.1080/14728214.2016.1257607","title":"Emerging drugs and therapeutics for systemic sclerosis","year":2016,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Systemic Sclerosis and Related Diseases","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Care; Western University","funders":"","keywords":"Medicine; Intensive care medicine; Disease; Context (archaeology); Scleroderma (fungus); Interstitial lung disease; Multiple sclerosis; Systemic disease; Bioinformatics; Immunology; Pathology; Lung; Internal medicine","score_opus":0.07706061920886499,"score_gpt":0.37317207486498655,"score_spread":0.29611145565612157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2548436673","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009374337,0.99622065,0.00018533294,0.0010550134,0.0006332215,0.000009252333,0.000026123236,0.000012566743,0.0017642202],"genre_scores_gemma":[0.00083841494,0.9960524,0.00030465476,0.00085529906,0.0005159368,0.000011395115,0.0000531278,0.00000228678,0.0013665743],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996119,0.00007829403,0.00004654375,0.00005341537,0.00017388855,0.000035963927],"domain_scores_gemma":[0.9995204,0.00020075546,0.00007832137,0.000014736711,0.00014434107,0.000041563253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069113134,0.0008387288,0.0011354889,0.0021028786,0.0002745764,0.00099152,0.000729543,0.0015539889,0.007942254],"category_scores_gemma":[0.0008893539,0.0001992557,0.00073525327,0.0013933363,0.00050406804,0.0013616814,0.00074526615,0.0030700078,0.0038640539],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006568873,0.0000628992,0.00010260117,0.016352734,0.00010250425,0.0002385692,0.00006421223,0.00030415092,0.0019860177,0.006373162,0.06398138,0.91036606],"study_design_scores_gemma":[0.000021161939,0.000064940454,0.00029558528,0.0042593903,0.00007528528,0.00089615857,0.000030436833,0.000099270284,0.0003183952,0.0023296438,0.9915979,0.000011858971],"about_ca_topic_score_codex":0.0007870147,"about_ca_topic_score_gemma":0.0017845681,"teacher_disagreement_score":0.007942254,"about_ca_system_score_codex":0.00073881214,"about_ca_system_score_gemma":0.0012178192,"threshold_uncertainty_score":0.026569486},"labels":[],"label_agreement":null},{"id":"W3023787781","doi":"10.1080/14728214.2020.1763954","title":"Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update","year":2020,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Medicine; Dyskinesia; Pharmacology; Intensive care medicine; Internal medicine; Disease; Parkinson's disease","score_opus":0.0638396933316561,"score_gpt":0.38957649571567515,"score_spread":0.32573680238401903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023787781","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007393436,0.99783486,0.00008507554,0.0005328211,0.000345414,0.0000071894056,0.00003800545,0.000009871923,0.0010729396],"genre_scores_gemma":[0.0004069006,0.9982034,0.00015578953,0.0004149319,0.00023167366,0.0000074157488,0.000049629434,0.0000016136637,0.0005285616],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997937,0.000039607345,0.000036479538,0.000032933833,0.000077382894,0.000019953884],"domain_scores_gemma":[0.9995871,0.0001871882,0.00006731992,0.0000079763095,0.00012044057,0.000029910632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050048943,0.0007912242,0.0012407824,0.0018995744,0.00020351622,0.0009848188,0.00077506376,0.001231336,0.0087214615],"category_scores_gemma":[0.0008167124,0.00020438235,0.00069115317,0.0017390795,0.00030220774,0.0012465804,0.0005486437,0.0019500388,0.003785114],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007836342,0.00005176291,0.00008235262,0.024666049,0.00009492035,0.00016624235,0.000046480134,0.00017211327,0.0008812636,0.001974786,0.050144605,0.92164105],"study_design_scores_gemma":[0.000029272489,0.00008763019,0.0004022947,0.0074226903,0.0001832153,0.00093771034,0.00003812478,0.0000740679,0.00015444189,0.0010052645,0.9896526,0.00001273837],"about_ca_topic_score_codex":0.0011457928,"about_ca_topic_score_gemma":0.0025602097,"teacher_disagreement_score":0.0087214615,"about_ca_system_score_codex":0.0005350844,"about_ca_system_score_gemma":0.0010067228,"threshold_uncertainty_score":0.029176235},"labels":[],"label_agreement":null},{"id":"W4230999927","doi":"10.1517/eoed.8.2.297.21133","title":"Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae","year":2003,"lang":"en","type":"article","venue":"Expert Opinion on Emerging Drugs","topic":"Pneumonia and Respiratory Infections","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre","funders":"","keywords":"Telithromycin; Ketolide; Streptococcus pneumoniae; Microbiology; Macrolide Antibiotics; Erythromycin; Efflux; Medicine; Antibiotics; Biology","score_opus":0.05614382737932102,"score_gpt":0.3787878638256813,"score_spread":0.3226440364463603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230999927","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.033959895,0.9325974,0.004846549,0.010963318,0.001508966,0.00010692688,0.0001895269,0.00019204851,0.015635427],"genre_scores_gemma":[0.119456075,0.8268935,0.010078366,0.008775099,0.0031149853,0.00013534377,0.00056713057,0.000042974945,0.030936534],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998933,0.000023029384,0.00001174279,0.000020454474,0.000033588025,0.000017824535],"domain_scores_gemma":[0.9999074,0.000015312547,0.000021661952,0.0000041426583,0.00002763676,0.000023835306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025509906,0.00039641417,0.00052882987,0.00042979865,0.0002184242,0.00055239914,0.00032943307,0.00084292307,0.0033214125],"category_scores_gemma":[0.00018582455,0.00009190078,0.00022194438,0.0002999104,0.00020489669,0.00061985635,0.0002486484,0.0008907842,0.0016759073],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009340173,0.00029260237,0.0008857248,0.0021215137,0.00004644102,0.0014219696,0.00008891527,0.00017496863,0.03800668,0.00231043,0.025182609,0.9285341],"study_design_scores_gemma":[0.00091407466,0.0033900156,0.008077527,0.0006586317,0.00018701734,0.012910789,0.00016622694,0.00072960666,0.019921187,0.0021145237,0.9508832,0.000047213518],"about_ca_topic_score_codex":0.0003028472,"about_ca_topic_score_gemma":0.001474115,"teacher_disagreement_score":0.0033214125,"about_ca_system_score_codex":0.0002984725,"about_ca_system_score_gemma":0.0003558901,"threshold_uncertainty_score":0.0111112},"labels":[],"label_agreement":null},{"id":"W4236574143","doi":"10.1517/14728214.12.3.461","title":"Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome","year":2007,"lang":"en","type":"article","venue":"Expert Opinion on Emerging Drugs","topic":"Respiratory Support and Mechanisms","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Centre; London Health Sciences Centre; Western University","funders":"National Institutes of Health","keywords":"Medicine; ARDS; Intensive care medicine; Population; Hypoxemia; Diffuse alveolar damage; Lung; Acute respiratory distress; Internal medicine","score_opus":0.022052531044507266,"score_gpt":0.3533447243498627,"score_spread":0.3312921933053554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236574143","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004631594,0.96129817,0.0047799614,0.013215428,0.002442779,0.00009388719,0.00007397159,0.000074518066,0.013389634],"genre_scores_gemma":[0.033528246,0.9281334,0.014997952,0.007892601,0.0040489216,0.00021328984,0.00029106814,0.000020462305,0.010874064],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997012,0.000097910175,0.000027506649,0.000027729338,0.00010793008,0.00003767376],"domain_scores_gemma":[0.9996997,0.00009501338,0.000057924084,0.000012169196,0.000099627505,0.0000355406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073301943,0.00055255264,0.00097543816,0.00075309625,0.0002499953,0.00052270014,0.0006947704,0.0013511942,0.0068451944],"category_scores_gemma":[0.0005900009,0.00010659433,0.00054515555,0.00038574188,0.00036314063,0.0008393252,0.00043795162,0.0020816422,0.0025237554],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006536893,0.0006242841,0.0006798153,0.0036622034,0.00018203708,0.0015778106,0.000108865606,0.0004028095,0.013547414,0.011285964,0.044236746,0.9230384],"study_design_scores_gemma":[0.001407358,0.001969446,0.0029256681,0.0017032484,0.00030858806,0.006629506,0.00016648934,0.0008952693,0.00533113,0.010507109,0.968115,0.000041082534],"about_ca_topic_score_codex":0.00025537284,"about_ca_topic_score_gemma":0.00091545016,"teacher_disagreement_score":0.0068451944,"about_ca_system_score_codex":0.00035446696,"about_ca_system_score_gemma":0.00046817586,"threshold_uncertainty_score":0.022899508},"labels":[],"label_agreement":null},{"id":"W4365811101","doi":"10.1080/14728214.2023.2203912","title":"Emerging drugs in the treatment of chronic cough","year":2023,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Respiratory and Cough-Related Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Chronic cough; Intensive care medicine; Narrative review; Disease; Expert opinion; Bioinformatics; Internal medicine; Asthma","score_opus":0.10327062259724018,"score_gpt":0.44266865039782566,"score_spread":0.3393980278005855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365811101","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012403949,0.9982942,0.00006923908,0.00027642227,0.00022021329,0.0000091852635,0.000026245103,0.000006170306,0.00097428175],"genre_scores_gemma":[0.0011580442,0.9976267,0.00013647179,0.00030135427,0.0001443157,0.000010658208,0.000038926995,0.0000013384301,0.0005821896],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997485,0.000057520654,0.000037561997,0.000038380356,0.00008973693,0.000028263652],"domain_scores_gemma":[0.99967194,0.0001657589,0.000059889167,0.0000072704256,0.00007676586,0.000018386138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045384,0.00050188607,0.0010393254,0.0015406001,0.00020587606,0.000791891,0.00054150063,0.00087737176,0.00733399],"category_scores_gemma":[0.0007519144,0.00014402016,0.0008880448,0.0010431912,0.00025533853,0.00072943413,0.00048880203,0.0015147446,0.0019570608],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012623493,0.000066927365,0.00012305261,0.045408502,0.00017664082,0.00017198577,0.00006435452,0.0002424054,0.001476361,0.002802531,0.023748722,0.9255924],"study_design_scores_gemma":[0.00006455449,0.00017764673,0.0008474008,0.018079996,0.0003477497,0.00117448,0.000067312336,0.0001334682,0.0005462678,0.0016498156,0.9768927,0.000018621042],"about_ca_topic_score_codex":0.0009023727,"about_ca_topic_score_gemma":0.0020949615,"teacher_disagreement_score":0.00733399,"about_ca_system_score_codex":0.00047355064,"about_ca_system_score_gemma":0.00089981715,"threshold_uncertainty_score":0.024534643},"labels":[],"label_agreement":null},{"id":"W4379598629","doi":"10.1080/14728214.2023.2218643","title":"Emerging peptide therapeutics for the treatment of ovarian cancer","year":2023,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ovarian cancer; Cancer; Peptide; Oncology; Internal medicine; Cancer research; Biology; Biochemistry","score_opus":0.09083098333692492,"score_gpt":0.4018117388492976,"score_spread":0.3109807555123727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379598629","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011561881,0.99866426,0.00008647037,0.00020519299,0.00018283847,0.000006576797,0.000013745893,0.000004192852,0.0007210955],"genre_scores_gemma":[0.0007998889,0.9981674,0.00013688239,0.00024865012,0.00013661999,0.000008750164,0.000027007105,0.0000010218623,0.00047373615],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998337,0.000031242715,0.000018644563,0.000024823916,0.00007199457,0.000019614798],"domain_scores_gemma":[0.9998511,0.00006007828,0.0000321167,0.0000033251215,0.00003866978,0.000014736118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042115012,0.0006518712,0.0010196986,0.0016240629,0.00018335627,0.00073981826,0.0005003354,0.000905563,0.0041940846],"category_scores_gemma":[0.00047789668,0.00014501426,0.00051477307,0.001348858,0.0003106419,0.0008327211,0.00050065,0.0016375895,0.0017940891],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000101871854,0.00006474356,0.000104740684,0.024187893,0.00010410533,0.00024127755,0.00004944887,0.00029991157,0.0037628838,0.0024168713,0.021190995,0.9474752],"study_design_scores_gemma":[0.000056805955,0.00020147933,0.00088572444,0.008080422,0.00017378345,0.0018148893,0.0000628011,0.00011946731,0.0011377054,0.0022017262,0.985247,0.000018117858],"about_ca_topic_score_codex":0.0006373073,"about_ca_topic_score_gemma":0.0011071728,"teacher_disagreement_score":0.0041940846,"about_ca_system_score_codex":0.00046899304,"about_ca_system_score_gemma":0.00066297915,"threshold_uncertainty_score":0.014030576},"labels":[],"label_agreement":null},{"id":"W4390744213","doi":"10.1080/14728214.2024.2303116","title":"Novel and emerging drugs for the treatment of Crohn’s disease: a review of phase II and III trials","year":2024,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Crohn's disease; Janus kinase; Clinical trial; Disease; Vedolizumab; Narrative review; Inflammatory bowel disease; Intensive care medicine; Bioinformatics; Pharmacology; Immunology; Internal medicine; Cytokine","score_opus":0.053323533352468054,"score_gpt":0.40743744765041623,"score_spread":0.3541139142979482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390744213","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010947814,0.99856645,0.0001019432,0.00032749938,0.0001990951,0.000029205852,0.000063530504,0.000006774067,0.0005961284],"genre_scores_gemma":[0.00075035554,0.99788815,0.00025618242,0.0005399853,0.00014495885,0.00003834955,0.00007766032,0.0000031355812,0.0003012677],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995105,0.0001408204,0.00009815287,0.00006649278,0.00014034056,0.00004363257],"domain_scores_gemma":[0.9987041,0.00074362505,0.00019569193,0.000026544178,0.00026237796,0.00006760952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017540875,0.0009215746,0.0023332648,0.0017651014,0.00022866775,0.0011129132,0.0012625477,0.0012302638,0.0061514494],"category_scores_gemma":[0.0024830692,0.00027404624,0.0018574214,0.0018917414,0.000345558,0.0010841468,0.0005670589,0.0017064031,0.001568979],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054538675,0.00008554021,0.00012245546,0.06906281,0.0004767468,0.000115830306,0.000045157933,0.00030760502,0.0011206095,0.0015302371,0.031153077,0.89543456],"study_design_scores_gemma":[0.0005643146,0.00086238823,0.0013516833,0.066730514,0.0027336634,0.0010862795,0.00007485517,0.00022662472,0.0008429788,0.001779565,0.9237019,0.00004530904],"about_ca_topic_score_codex":0.0008317454,"about_ca_topic_score_gemma":0.0020959575,"teacher_disagreement_score":0.0061514494,"about_ca_system_score_codex":0.00077919156,"about_ca_system_score_gemma":0.0018523935,"threshold_uncertainty_score":0.020578623},"labels":[],"label_agreement":null},{"id":"W4391402131","doi":"10.1080/14728214.2024.2312817","title":"How will tovorafenib change our treatment of pediatric low-grade glioma?","year":2024,"lang":"en","type":"editorial","venue":"Expert Opinion on Emerging Drugs","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Glioma; Oncology; Intensive care medicine; Cancer research","score_opus":0.034070190485886775,"score_gpt":0.3377245327762583,"score_spread":0.3036543422903715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391402131","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021239623,0.087463,0.0003591408,0.1103382,0.7960927,0.000059887177,0.00021741565,0.0001358873,0.005121335],"genre_scores_gemma":[0.0017548722,0.09624873,0.00050129177,0.12923504,0.75556463,0.00007475357,0.0002450374,0.000088971574,0.01628662],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987808,0.00026182266,0.00019028725,0.00012516457,0.0005110424,0.00013092926],"domain_scores_gemma":[0.9947707,0.0021508744,0.00032797558,0.000096654905,0.002030781,0.0006229317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003333086,0.0011717489,0.0019787645,0.0010893906,0.0008642998,0.0023551916,0.0023207434,0.0065767705,0.0076019005],"category_scores_gemma":[0.010632203,0.0003947579,0.001747627,0.00051378825,0.00083694485,0.0029527813,0.00060528656,0.011291922,0.006854131],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007996466,0.000014304969,0.000029381128,0.0006724093,0.000042011096,0.00009638397,0.000010217306,0.00004006468,0.00009922735,0.0004449865,0.9666549,0.03181602],"study_design_scores_gemma":[0.00014341432,0.00007322351,0.00023729599,0.0008278397,0.00013428568,0.00032414388,0.00002380702,0.00011917289,0.00014349696,0.0013344083,0.996619,0.000020060026],"about_ca_topic_score_codex":0.0013728158,"about_ca_topic_score_gemma":0.004100837,"teacher_disagreement_score":0.0076019005,"about_ca_system_score_codex":0.0017058257,"about_ca_system_score_gemma":0.0019014783,"threshold_uncertainty_score":0.025430858},"labels":[],"label_agreement":null},{"id":"W4394581977","doi":"10.1080/14728214.2024.2340723","title":"Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trials","year":2024,"lang":"en","type":"article","venue":"Expert Opinion on Emerging Drugs","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton; Dalhousie University","funders":"","keywords":"Medicine; Idiopathic pulmonary fibrosis; Nintedanib; Pirfenidone; Clinical trial; Intensive care medicine; Pulmonary fibrosis; Disease; Lung; Internal medicine; Fibrosis","score_opus":0.07169041454626408,"score_gpt":0.436137698945395,"score_spread":0.36444728439913093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394581977","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00059950445,0.990209,0.00041638568,0.0042443583,0.0009015382,0.00019807773,0.00034719726,0.00003982996,0.0030441226],"genre_scores_gemma":[0.004086166,0.9846065,0.0014448551,0.0066534304,0.0008748505,0.0003917091,0.00049815903,0.000024957408,0.0014194079],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99885726,0.00040352606,0.00020332813,0.00009000835,0.00032054118,0.00012524259],"domain_scores_gemma":[0.99653375,0.0014975878,0.0007140637,0.000089053945,0.0009047485,0.0002607055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037392196,0.00087604724,0.0032288881,0.001342849,0.00035132773,0.0023928268,0.0015526081,0.0022625616,0.010009251],"category_scores_gemma":[0.004765248,0.00032938656,0.0027534463,0.0017237352,0.0005574402,0.0020868499,0.0009176601,0.0031849637,0.0028131346],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016869003,0.00033116955,0.00039475484,0.04452884,0.00058551726,0.00017622097,0.000082376704,0.00031408807,0.0019730122,0.0025491845,0.066187695,0.88119036],"study_design_scores_gemma":[0.0031544976,0.0030863709,0.002324362,0.09027294,0.0032294556,0.0009566589,0.00016863462,0.00047739974,0.001261878,0.0042777136,0.89072096,0.00006916832],"about_ca_topic_score_codex":0.000876463,"about_ca_topic_score_gemma":0.002902538,"teacher_disagreement_score":0.010009251,"about_ca_system_score_codex":0.0010989535,"about_ca_system_score_gemma":0.0026000065,"threshold_uncertainty_score":0.03348428},"labels":[],"label_agreement":null},{"id":"W4394816071","doi":"10.1080/14728214.2024.2339906","title":"Emerging monoclonal antibody therapy for head and neck squamous cell carcinoma","year":2024,"lang":"en","type":"article","venue":"Expert Opinion on Emerging Drugs","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Head and neck squamous-cell carcinoma; Oncology; Internal medicine; Head and neck; Incidence (geometry); Monoclonal antibody; Head and neck cancer; Immunotherapy; Antibody; Cancer; Immunology; Surgery","score_opus":0.030195221107428807,"score_gpt":0.3631607518519307,"score_spread":0.3329655307445019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394816071","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018379064,0.9810647,0.0006182011,0.00706822,0.002267104,0.000030329245,0.00009500264,0.000032620494,0.006985952],"genre_scores_gemma":[0.017778434,0.9636356,0.0011666446,0.0066054496,0.0032704414,0.000038669732,0.00028270655,0.000008224723,0.007213825],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998338,0.000039944494,0.0000130144035,0.000021394699,0.0000702267,0.000021664591],"domain_scores_gemma":[0.9997851,0.000059293678,0.0000354712,0.0000046365353,0.00008966135,0.000025842619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053114654,0.00026604455,0.00044593346,0.00037176395,0.0001219731,0.000552673,0.00037018643,0.0007453422,0.0047815987],"category_scores_gemma":[0.0005484442,0.00006286552,0.00037315759,0.0002668483,0.00017672962,0.00064420974,0.00024905935,0.0011427184,0.0021000598],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000254983,0.00007690943,0.0004860691,0.005055534,0.00010876608,0.00038403535,0.000035918318,0.00028980922,0.0057964996,0.003329372,0.08763798,0.8965441],"study_design_scores_gemma":[0.00012334876,0.00038489018,0.001112366,0.0015470869,0.000118334305,0.0013314222,0.000039055347,0.00025291834,0.0016401047,0.0017901507,0.9916496,0.000010714104],"about_ca_topic_score_codex":0.0005653778,"about_ca_topic_score_gemma":0.0021296283,"teacher_disagreement_score":0.0047815987,"about_ca_system_score_codex":0.00054427655,"about_ca_system_score_gemma":0.0005062999,"threshold_uncertainty_score":0.015996039},"labels":[],"label_agreement":null},{"id":"W4395667067","doi":"10.1080/14728214.2024.2346590","title":"Emerging and traditional 5-α reductase inhibitors and androgen receptor antagonists for male androgenetic alopecia","year":2024,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mediprobe Research (Canada); University of Toronto","funders":"","keywords":"Androgen receptor; Medicine; 5 Alpha-Reductase Inhibitor; Androgen; Finasteride; Pharmacology; Receptor; Internal medicine; Endocrinology; Prostate cancer; Hormone; Cancer","score_opus":0.04625012959276738,"score_gpt":0.35280377971852367,"score_spread":0.3065536501257563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395667067","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012768476,0.9977416,0.00010962958,0.0005103675,0.00027574465,0.000008303682,0.000027606262,0.000008381988,0.0011907383],"genre_scores_gemma":[0.0010042025,0.9969663,0.00019766566,0.0005343436,0.00028078526,0.000008368617,0.000047526475,0.0000019564654,0.00095882366],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997769,0.000042588563,0.000026186905,0.000036051355,0.00009831771,0.000019891819],"domain_scores_gemma":[0.9997067,0.00011993606,0.000062210085,0.0000056621834,0.000086872074,0.000018609244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045005747,0.0005168306,0.0008566447,0.0014056922,0.00017510325,0.00067356817,0.00065633404,0.0008545976,0.008101118],"category_scores_gemma":[0.000711979,0.00013872063,0.0008026368,0.0009297122,0.00022940016,0.00075060216,0.00038386442,0.0015636308,0.0024286094],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009540216,0.000055690747,0.000111455396,0.02461363,0.0001441163,0.00015367164,0.000041448497,0.00017719154,0.0013855512,0.001923696,0.03379878,0.9374994],"study_design_scores_gemma":[0.000074523035,0.0001640762,0.0009086967,0.0118608605,0.00034678334,0.0014042088,0.00006516898,0.0001257047,0.00047562452,0.0015336826,0.98302346,0.000017315619],"about_ca_topic_score_codex":0.00094547315,"about_ca_topic_score_gemma":0.0025674137,"teacher_disagreement_score":0.008101118,"about_ca_system_score_codex":0.00038931373,"about_ca_system_score_gemma":0.00067209336,"threshold_uncertainty_score":0.02710092},"labels":[],"label_agreement":null},{"id":"W4399261264","doi":"10.1080/14728214.2024.2363215","title":"Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer’s disease","year":2024,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"Weston Brain Institute","keywords":"Apathy; Medicine; Psychosis; Psychiatry; Disease; Adverse effect; Dementia; Cognitive decline; Alzheimer's disease; Intensive care medicine; Cognition; Pharmacology; Internal medicine","score_opus":0.10897566365268613,"score_gpt":0.47564281046541634,"score_spread":0.3666671468127302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399261264","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007963107,0.9985158,0.00007820237,0.000347011,0.00020124244,0.000009960879,0.00002279207,0.0000060636858,0.0007392886],"genre_scores_gemma":[0.00062808295,0.9982009,0.00017089884,0.00036695795,0.00014994903,0.000011785431,0.000030336776,0.0000010951197,0.00044001767],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997193,0.000060845257,0.00004571333,0.000038646544,0.00011263279,0.000022772756],"domain_scores_gemma":[0.99966145,0.00015697075,0.00007125015,0.0000066866296,0.00008641147,0.000017297412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005609361,0.00071912067,0.0012743414,0.0015225998,0.00018721048,0.00076367246,0.0007509524,0.0012080957,0.0061538494],"category_scores_gemma":[0.00087410444,0.00015950015,0.0008757789,0.0010901194,0.00028755615,0.0007891603,0.0004807381,0.001594804,0.0019570384],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008742114,0.000056783523,0.00007402931,0.051382672,0.00021306121,0.00013397117,0.000062271196,0.00020789377,0.0010625012,0.0020083787,0.029775444,0.9149356],"study_design_scores_gemma":[0.00010824204,0.00018982925,0.00091533054,0.03291969,0.0006553252,0.0012044369,0.000094812,0.00015226351,0.000396217,0.0025028337,0.96083814,0.00002279558],"about_ca_topic_score_codex":0.0010518308,"about_ca_topic_score_gemma":0.0029293378,"teacher_disagreement_score":0.0061538494,"about_ca_system_score_codex":0.0005073567,"about_ca_system_score_gemma":0.00097570365,"threshold_uncertainty_score":0.02058667},"labels":[],"label_agreement":null},{"id":"W4399385857","doi":"10.1080/14728214.2024.2363213","title":"Emerging drugs for the treatment of benign prostatic hyperplasia: a 2023 update","year":2024,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Université de Montréal","funders":"","keywords":"Medicine; Lower urinary tract symptoms; Hyperplasia; cGMP-specific phosphodiesterase type 5; Benign prostatic hyperplasia (BPH); Intensive care medicine; Primary care; Primary treatment; Modalities; 5 Alpha-Reductase Inhibitor; Urology; Prostate; Internal medicine; Gynecology; Erectile dysfunction; Finasteride; Cancer; Family medicine","score_opus":0.07313921420710602,"score_gpt":0.4351080879869832,"score_spread":0.3619688737798772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399385857","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000070086055,0.99830365,0.000045560006,0.00047423685,0.00030639346,0.0000113854285,0.000039970066,0.0000069855937,0.0007416515],"genre_scores_gemma":[0.00034445882,0.99856156,0.00013836547,0.00042649248,0.00016972353,0.000010130524,0.000047897152,0.0000015156613,0.00029984466],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994165,0.00012440652,0.00012879078,0.000060541057,0.00022352189,0.00004634969],"domain_scores_gemma":[0.99840564,0.00083451526,0.00028316074,0.000026725327,0.00038129705,0.0000687114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012384593,0.000904754,0.001846603,0.004069724,0.00031904996,0.0013685406,0.0009786903,0.0016424716,0.009103389],"category_scores_gemma":[0.0022520712,0.00031161422,0.0014493797,0.0038081014,0.00039435434,0.0016437593,0.00074872724,0.0017440395,0.0023335158],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012916503,0.00005616998,0.00014061839,0.11029877,0.00021735893,0.00018770402,0.00008328465,0.00016382878,0.00078844244,0.0017619486,0.044575196,0.8415975],"study_design_scores_gemma":[0.000054095763,0.00015681099,0.0011407627,0.07781265,0.0010269723,0.0011669829,0.000099819525,0.00009758954,0.00021906527,0.0011072913,0.91709524,0.000022788408],"about_ca_topic_score_codex":0.0018911931,"about_ca_topic_score_gemma":0.005104042,"teacher_disagreement_score":0.009103389,"about_ca_system_score_codex":0.0010459068,"about_ca_system_score_gemma":0.0028563903,"threshold_uncertainty_score":0.03045386},"labels":[],"label_agreement":null},{"id":"W4404445324","doi":"10.1080/14728214.2024.2426649","title":"ONC201 (Dordaviprone): review of evidence to date in diffuse midline glioma, hope or hype?","year":2024,"lang":"en","type":"editorial","venue":"Expert Opinion on Emerging Drugs","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; McGill University; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Glioma; Cancer research","score_opus":0.06663130938689137,"score_gpt":0.4072833999992634,"score_spread":0.340652090612372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404445324","genre_codex":"review","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016257109,0.60170996,0.00027041137,0.045218293,0.3475972,0.00006747988,0.0002693457,0.000096906355,0.0046078633],"genre_scores_gemma":[0.001773891,0.59550124,0.00042031446,0.06448861,0.3249939,0.0000958087,0.00032893612,0.00006020761,0.012337059],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990945,0.00025171827,0.00015585353,0.000099332174,0.0003310242,0.00006757],"domain_scores_gemma":[0.996711,0.0015924061,0.0003171585,0.000043849108,0.0010888312,0.0002467052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002504392,0.0012259078,0.0025325082,0.001426639,0.00064451096,0.002236879,0.0020993822,0.0038446344,0.009067415],"category_scores_gemma":[0.007745166,0.00032843926,0.0014147311,0.0011627339,0.0007091549,0.002214446,0.00067534094,0.0054548206,0.006126084],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020762069,0.000014303847,0.000026930873,0.006271405,0.000113187765,0.00010303339,0.000019335577,0.000038514572,0.00012556507,0.00054525345,0.904766,0.08776876],"study_design_scores_gemma":[0.00023666344,0.00010372183,0.00030274477,0.006566256,0.00043423419,0.00048738293,0.000043305252,0.00009297876,0.00013891871,0.0011783943,0.9903922,0.000023286024],"about_ca_topic_score_codex":0.001463264,"about_ca_topic_score_gemma":0.003801154,"teacher_disagreement_score":0.009067415,"about_ca_system_score_codex":0.0012323739,"about_ca_system_score_gemma":0.0019480323,"threshold_uncertainty_score":0.030333519},"labels":[],"label_agreement":null},{"id":"W4406242635","doi":"10.1080/14728214.2025.2452514","title":"Seltorexant for major depressive disorder","year":2025,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Sleep and Wakefulness Research","field":"Neuroscience","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Brain and Cognition Discovery Foundation; University Health Network","funders":"","keywords":"Major depressive disorder; Tolerability; Orexin; Medicine; Preclinical research; Cognition; Psychiatry; Neuroscience; Pharmacology; Clinical psychology; Psychology; Internal medicine; Receptor; Adverse effect; Neuropeptide","score_opus":0.07306809664989065,"score_gpt":0.42136772834151154,"score_spread":0.34829963169162087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406242635","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011790587,0.9987332,0.000041868465,0.00014746824,0.000100207115,0.000016868285,0.000051445928,0.000006193765,0.00078475196],"genre_scores_gemma":[0.0021298486,0.9964948,0.00014548303,0.00043361052,0.00010296869,0.000028209924,0.00008196394,0.000001642594,0.00058153324],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997328,0.0000702551,0.00007039325,0.000042173106,0.00006668749,0.000017543167],"domain_scores_gemma":[0.99968743,0.00016295753,0.000093021634,0.0000049087557,0.00003611733,0.000015574931],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053193845,0.00067125604,0.0015687443,0.0018630505,0.00017879989,0.0006131998,0.0006917291,0.00073227304,0.010240315],"category_scores_gemma":[0.0010265743,0.00016702662,0.0011091533,0.001396445,0.00024508752,0.000464588,0.00048549098,0.0008395184,0.0018197127],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026937923,0.000034146597,0.00010664336,0.19840167,0.00065394666,0.00017179608,0.00004780082,0.00016166615,0.0006434123,0.0010661931,0.022636145,0.77580714],"study_design_scores_gemma":[0.00070936256,0.00044450935,0.0033878915,0.17205651,0.0046173325,0.0024025582,0.00013455054,0.00018778483,0.00082827057,0.0019957894,0.81320035,0.000035114135],"about_ca_topic_score_codex":0.0011524057,"about_ca_topic_score_gemma":0.0031143052,"teacher_disagreement_score":0.010240315,"about_ca_system_score_codex":0.0004715491,"about_ca_system_score_gemma":0.0008604365,"threshold_uncertainty_score":0.034257293},"labels":[],"label_agreement":null},{"id":"W4411195516","doi":"10.1080/14728214.2025.2517582","title":"Motor fluctuations in Parkinson disease – a mini-review of emerging drugs","year":2025,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Neurological disorders and treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Parkinson's Clinic of Eastern Toronto & Movement Disorders Centre; Toronto Western Hospital; Public Health Ontario; University of Toronto","funders":"","keywords":"Medicine; Parkinson's disease; Disease; Physical medicine and rehabilitation; Neuroscience; Intensive care medicine; Internal medicine; Psychology","score_opus":0.03519880348203243,"score_gpt":0.37833576729104834,"score_spread":0.3431369638090159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411195516","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005866047,0.99882907,0.00004600069,0.00029446237,0.00025649514,0.0000066150933,0.00002187037,0.000004809926,0.00048201322],"genre_scores_gemma":[0.00038714282,0.9985984,0.00011256897,0.0002473542,0.0002594379,0.000008179267,0.000034827306,0.0000013120004,0.0003507257],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99972516,0.00004910423,0.000052601477,0.000042411917,0.00010408828,0.000026650878],"domain_scores_gemma":[0.9994325,0.00028794535,0.00009640611,0.000012044289,0.00013728335,0.000033891403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006993355,0.0009093583,0.0015819436,0.0022700669,0.00023802462,0.001119278,0.0008957693,0.0010816283,0.0066790916],"category_scores_gemma":[0.00091211253,0.00028018054,0.0009303644,0.0017089824,0.0003537342,0.0013277928,0.00062444614,0.0017014893,0.0020578708],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011076913,0.00006401856,0.00010679172,0.0538453,0.00016147875,0.00016515605,0.00007054511,0.00024574948,0.00087960495,0.0021015767,0.048865315,0.8933836],"study_design_scores_gemma":[0.000035076788,0.00014032066,0.00067881664,0.017732503,0.00030853934,0.0011245825,0.00006839472,0.000105235435,0.0001847836,0.001476902,0.9781251,0.00001962341],"about_ca_topic_score_codex":0.0010035277,"about_ca_topic_score_gemma":0.0023914273,"teacher_disagreement_score":0.0066790916,"about_ca_system_score_codex":0.0005438858,"about_ca_system_score_gemma":0.0012499469,"threshold_uncertainty_score":0.022343755},"labels":[],"label_agreement":null},{"id":"W4414443225","doi":"10.1080/14728214.2025.2565189","title":"Future treatments for myelin oligodendrocyte glycoprotein antibody-associated disease: the clinical trial landscape","year":2025,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Clinical trial; Myelin oligodendrocyte glycoprotein; Multiple sclerosis; Immunotherapy; Clinical neurology; Targeted therapy; Disease; MEDLINE","score_opus":0.11938186467696922,"score_gpt":0.4944612600731487,"score_spread":0.3750793953961795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414443225","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001501926,0.99450076,0.00017546538,0.0036012775,0.0004571532,0.00004295558,0.00005276537,0.000011047529,0.0010084108],"genre_scores_gemma":[0.0019819268,0.9916897,0.0007136022,0.0042170365,0.00064317056,0.00013344998,0.00010515785,0.0000075051685,0.00050846045],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99790925,0.0011059565,0.00028349052,0.00016824249,0.00043598557,0.00009708274],"domain_scores_gemma":[0.9911203,0.006153001,0.0008762237,0.00013061056,0.001444708,0.00027519194],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0067849103,0.00064903294,0.002414115,0.0011576087,0.0002756631,0.0017800658,0.001387701,0.0023581043,0.00821988],"category_scores_gemma":[0.010323825,0.00024099831,0.0016423536,0.0013064663,0.0006070333,0.002215735,0.0007056493,0.0027631198,0.0018115529],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005709099,0.00009253703,0.00015720482,0.06635488,0.00040443326,0.000093806404,0.000076599725,0.0002970258,0.00072760537,0.0054442794,0.041834008,0.8839468],"study_design_scores_gemma":[0.0010050846,0.0007276887,0.0009097601,0.12975802,0.0016382274,0.000582926,0.00016565072,0.00031459605,0.00045361422,0.0069535323,0.8574503,0.00004053461],"about_ca_topic_score_codex":0.0008573372,"about_ca_topic_score_gemma":0.0024304953,"teacher_disagreement_score":0.9932151,"about_ca_system_score_codex":0.0011983475,"about_ca_system_score_gemma":0.00401293,"threshold_uncertainty_score":0.035882473},"labels":[],"label_agreement":null}]}